Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04208698 · ClinicalTrials.gov registry record · Phase 2
A Scintigraphy Study in Adults With Diabetic Gastroparesis
A Phase 2 study, sponsored by CinDome Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04208698 is a Phase 2 study that was terminated before completion, run by CinDome Pharma. The registered enrollment target is 2 participants.
The verdict
NCT04208698, a Phase 2 study, was terminated before completion, sponsored by CinDome Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
Interventions
- DRUG CIN-102 Dose 1
- DRUG CIN-102 Dose 2
- DRUG Placebo for CIN-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2020-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04208698
The ClinicalTrials.gov registry entry for NCT04208698 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CinDome Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CIN-102 Dose 1 is the first listed.
NCT04208698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04208698 about?
NCT04208698 is a clinical study titled "A Scintigraphy Study in Adults With Diabetic Gastroparesis". This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
What is the current status of trial NCT04208698?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-02-17. Estimated completion is 2020-03-31.
What interventions are being tested in trial NCT04208698?
The interventions under investigation include: CIN-102 Dose 1 (DRUG), CIN-102 Dose 2 (DRUG), Placebo for CIN-102 (DRUG).
Who is sponsoring clinical trial NCT04208698?
This trial is sponsored by CinDome Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.